Background Immune checkpoint inhibitors (ICIs) are widely used in various tumor patients at present. Although the application of them demonstrates remarkable efficacy, ICIs can also result in some immune-related adverse events (irAEs) involving almost all the organs of the body, among which ICI-related pneumonitis (ICIP) is one main area of concerns. However, there has been no bibliometric analysis in this field so far. This study is designed to provide the basics of the knowledge framework and research frontiers about ICIP through bibliometrics. Method To learn more about ICIs development, publications from 2011 to 2022 were retrieved from Web of Science Core Collection (WOSCC) database. Microsoft Office Excel 2021 was used to conduct quantitative analysis of publication. Meanwhile, VOSviewers, CiteSpace and R package “bibliometrix” were used to perform bibliometric data analysis. Results 746 articles from 53 countries headed by United states and China were included. The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center and Harvard Medical School were the main research institutions. Frontiers in Oncology was the most popular journal in this field, and Journal of Clinical Oncology was the most frequently cited journal. These publications came from 5251 authors among whom Naidoo Jarushka, Hodi F Stephen and Nishino Mizuki had the most publications and Brahmer Julie R was the highest co-cited author. “Risk factors”, “efficacy”, “management”, and “radiological features” were the primary keywords of research hotspots and frontiers. Conclusion This is the first bibliometric study that comprehensively illustrates the development trends of ICIP, identifying recent hot directions and providing a reference for scholars studying this field.